DFC_MK-7339-008
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane
(Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance
Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
(NSCLC)
Protocol Number:
In male and female participants with stage IV squamous NSCLC with stable disease, partial
response, or complete response following induction treatment with pembrolizumab combined
with carboplatin and a taxane (paclitaxel or nab-paclitaxel):
Phase III
NCT03976362
Cancer
Lung
Raul Mena, M.D.
- John Wayne Cancer Institute (JWCI)
- Providence Los Angeles Research Center